omeprazole has been researched along with fluvoxamine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Checovich, WJ; Guengerich, FP; Inoue, K; Shaw, PM; Shimada, T; Yamazaki, H | 1 |
| Andersson, K; Bertilsson, L; Carrillo, JA; Christensen, M; Dahl, ML; Mihara, K; Ramos, SI; Tybring, G; Yasui-Furokori, N | 1 |
| Inoue, Y; Kaneko, S; Nakagami, T; Takahata, T; Tateishi, T; Yasui-Furukori, N; Yoshiya, G | 1 |
| Saito, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Shimizu, M; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Kaneko, S; Niioka, T; Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Niioka, T | 1 |
| Namiki, N; Tanaka, S; Uchida, S | 1 |
| Hu, HH; Jiang, HD; Kong, LM; Xu, SY; Yu, LS; Zeng, S; Zhou, H | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Miyakawa, S; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H | 1 |
1 review(s) available for omeprazole and fluvoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for omeprazole and fluvoxamine
| Article | Year |
|---|---|
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Topics: Adrenergic Agents; Adult; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2002 |
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Topics: Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Interactions; Female; Fluvoxamine; Heterozygote; Homozygote; Humans; Male; Mixed Function Oxygenases; Omeprazole; Selective Serotonin Reuptake Inhibitors | 2004 |
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors | 2004 |
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Enzyme Inhibitors; Female; Fluvoxamine; Heterozygote; Homozygote; Humans; Male; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Selective Serotonin Reuptake Inhibitors | 2006 |
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2006 |
13 other study(ies) available for omeprazole and fluvoxamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Topics: Animals; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fluvoxamine; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Rabbits; Recombinant Proteins; Sulfaphenazole | 1997 |
Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Specimen Collection; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Monitoring; Fluvoxamine; Genotype; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2011 |
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley | 2014 |
Identification of CYP2C19 inhibitors from phytochemicals using the recombinant human enzyme model.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cells, Cultured; Chromatography, High Pressure Liquid; Cyclooctanes; Cytochrome P-450 CYP2C19; Data Interpretation, Statistical; Enzyme Inhibitors; Fluvoxamine; Humans; Insecta; Lignans; Microsomes, Liver; Omeprazole; Plant Preparations; Polycyclic Compounds; Recombinant Proteins; Sesquiterpenes; Ticlopidine | 2014 |
Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
Topics: Adult; Alleles; Cytochrome P-450 CYP2C19; Drug Interactions; Fluvoxamine; Genetic Association Studies; Genotype; Humans; Male; Omeprazole; Proton Pump Inhibitors; Rifampin; Young Adult | 2019 |